News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
215,348 Results
Type
Article (7809)
Company Profile (38)
Press Release (207501)
Section
Business (57473)
Career Advice (182)
Deals (10965)
Drug Delivery (46)
Drug Development (13141)
Employer Resources (42)
FDA (5884)
Job Trends (5520)
News (89951)
Policy (8903)
Tag
2024 BioCapital Digital (1)
2024 BioMidwest Digital (2)
2024 Bio NC Digital (1)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (1)
2024 Genetown Standard (2)
2024 Lone Star Bio Digital (1)
2024 Pharm Country Digital (1)
2024 Pharm Country Standard (2)
2025 Lone Star Bio Digital (1)
2026 BioCapital Elite (1)
2026 BioCapital Standard (1)
Academia (732)
Adcomms (1)
Allergies (31)
Alliances (15846)
ALS (13)
Alzheimer's disease (325)
Antibody-drug conjugate (ADC) (24)
Approvals (5937)
Artificial intelligence (142)
Autoimmune disease (5)
Automation (3)
Bankruptcy (70)
Best Places to Work (4986)
BIOSECURE Act (6)
Biosimilars (55)
Biotechnology (20)
Bladder cancer (21)
Brain cancer (3)
Breast cancer (88)
Cancer (547)
Cardiovascular disease (68)
Career advice (174)
Career pathing (1)
CAR-T (22)
Cell therapy (84)
Cervical cancer (7)
Clinical research (11152)
Collaboration (286)
Compensation (24)
Complete response letters (2)
COVID-19 (751)
CRISPR (14)
C-suite (98)
Cystic fibrosis (18)
Data (606)
Decentralized trials (1)
Denatured (9)
Depression (12)
Diabetes (85)
Diagnostics (3210)
Digital health (11)
Diversity (3)
Diversity, equity & inclusion (14)
Drug discovery (34)
Drug pricing (46)
Drug shortages (6)
Duchenne muscular dystrophy (30)
Earnings (18357)
Editorial (15)
Employer branding (6)
Employer resources (38)
Events (48504)
Executive appointments (288)
FDA (6324)
Featured Employer (10)
Frontotemporal dementia (3)
Funding (267)
Gene editing (28)
Generative AI (16)
Gene therapy (70)
GLP-1 (179)
Government (1383)
Grass and pollen (2)
Guidances (26)
Healthcare (8690)
Huntington's disease (2)
IgA nephropathy (10)
Immunology and inflammation (18)
Indications (11)
Infectious disease (799)
Inflammatory bowel disease (38)
Inflation Reduction Act (5)
Influenza (12)
Intellectual property (20)
Interviews (15)
IPO (4421)
IRA (16)
Job creations (759)
Job search strategy (162)
Kidney cancer (1)
Labor market (4)
Layoffs (105)
Leadership (1)
Legal (1740)
Liver cancer (24)
Lung cancer (76)
Lymphoma (34)
Machine learning (2)
Management (14)
Manufacturing (70)
MASH (19)
Medical device (6154)
Medtech (6154)
Mergers & acquisitions (6793)
Metabolic disorders (221)
Multiple sclerosis (31)
NASH (5)
Neurodegenerative disease (17)
Neuropsychiatric disorders (6)
Neuroscience (444)
NextGen: Class of 2025 (2950)
Non-profit (1566)
Northern California (770)
Now hiring (2)
Obesity (121)
Opinion (70)
Ovarian cancer (14)
Pain (18)
Pancreatic cancer (12)
Parkinson's disease (22)
Partnered (7)
Patents (36)
Patient recruitment (30)
Peanut (19)
People (19275)
Pharmaceutical (12)
Pharmacy benefit managers (8)
Phase I (2470)
Phase II (3944)
Phase III (5256)
Pipeline (359)
Podcasts (31)
Policy (43)
Postmarket research (770)
Preclinical (764)
Press Release (10)
Prostate cancer (38)
Psychedelics (5)
Radiopharmaceuticals (79)
Rare diseases (103)
Real estate (1456)
Recruiting (13)
Regulatory (6439)
Reports (18)
Research institute (651)
Resumes & cover letters (14)
Rett syndrome (2)
RNA editing (1)
RSV (16)
Schizophrenia (18)
Series A (41)
Series B (38)
Service/supplier (3)
Sickle cell disease (26)
Southern California (640)
Special edition (7)
Spinal muscular atrophy (35)
Sponsored (6)
Startups (1280)
Stomach cancer (2)
Supply chain (22)
The Weekly (22)
United States (7403)
Vaccines (150)
Venture capitalists (17)
Webinars (4)
Weight loss (65)
Women's health (22)
Worklife (2)
Date
Today (107)
Last 7 days (268)
Last 30 days (999)
Last 365 days (12063)
2025 (3299)
2024 (12190)
2023 (13327)
2022 (20627)
2021 (21988)
2020 (21382)
2019 (18189)
2018 (13378)
2017 (9329)
2016 (9866)
2015 (11264)
2014 (8266)
2013 (6832)
2012 (7144)
2011 (7098)
2010 (5728)
Location
Africa (237)
Alabama (13)
Alaska (1)
Arizona (66)
Arkansas (6)
Asia (11298)
Australia (1517)
California (1708)
Canada (594)
China (164)
Colorado (114)
Connecticut (85)
Delaware (44)
Europe (27753)
Florida (297)
Georgia (86)
Hawaii (1)
Idaho (20)
Illinois (211)
India (16)
Indiana (134)
Iowa (1)
Japan (75)
Kansas (25)
Kentucky (13)
Louisiana (6)
Maine (26)
Maryland (218)
Massachusetts (1394)
Michigan (87)
Minnesota (128)
Mississippi (2)
Missouri (54)
Montana (5)
Nebraska (13)
Nevada (15)
New Hampshire (24)
New Jersey (641)
New Mexico (7)
New York (578)
North Carolina (400)
North Dakota (1)
Northern California (770)
Ohio (62)
Oklahoma (6)
Oregon (11)
Pennsylvania (485)
Puerto Rico (4)
Rhode Island (7)
South America (316)
South Carolina (8)
Southern California (640)
Tennessee (64)
Texas (237)
Utah (100)
Virginia (38)
Washington D.C. (25)
Washington State (142)
West Virginia (3)
Wisconsin (23)
215,348 Results for "bayer healthcare".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Clinical research
Bayer’s Kidney Disease Drug Kerendia Reduces Cardiovascular Risk by 16%
Bayer’s Kerendia, at the center of a $3 billion sales forecast, reduced the risk of cardiovascular death and heart failure in a Phase III trial.
September 3, 2024
·
2 min read
·
Annalee Armstrong
Postmarket research
Regeneron, Bayer Build Retinal Vein Occlusion Case for Eylea as Biosimilar Pressure Mounts
The Phase III win could help Regeneron and Bayer expand into retinal vein occlusion, a move that the partners need to help shore up sales of their Eylea franchise amid biosimilar encroachment.
December 17, 2024
·
2 min read
·
Tristan Manalac
China
Bayer Jumps on Chinese Partnership Train with Oncology Deal
The German conglomerate announced a licensing agreement with Puhe BioPharma for a PRMT5 inhibitor used in a variety of cancers. Financial details of the deal were not disclosed.
March 26, 2025
·
1 min read
·
Dan Samorodnitsky
Layoffs
Bayer to Lay Off 150 in Basel, Switzerland
The Switzerland layoffs are the latest in Bayer’s 2024 workforce reductions, which already include 1,500 people and nearly half of the executive leadership team.
August 26, 2024
·
1 min read
·
Angela Gabriel
Earnings
Bayer Earnings ‘Not Pretty,’ CEO Bill Anderson Admits As He Urges Calm
Bayer reported a decline of 37% in earnings per share on Tuesday, which sent its stock down 12%. CEO Bill Anderson urged investors to be patient as the company executes on a performance-boosting strategy outlined in March.
November 12, 2024
·
2 min read
·
Annalee Armstrong
Press Releases
Bayer’s Pharma Growth Strategy Progressing Well as Pipeline Advances
January 14, 2025
·
11 min read
Startups
Roivant Creates New ‘Vant’ to License Bayer’s Pulmonary Hypertension Drug
Under an in-license agreement worth up to $294 million, Roivant Sciences gains exclusive worldwide rights from Bayer to develop and commercialize mosliciguat, a potential first-in-class inhaled soluble guanylate cyclase activator.
September 10, 2024
·
2 min read
·
Tristan Manalac
Layoffs
Bayer, J&J and Pfizer to Lay Off Nearly 500 Combined Employees
Big Pharma companies Bayer and Johnson & Johnson are downsizing their New Jersey workforces while Pfizer cuts jobs in Ireland. Many of the layoffs are effective by the end of the year.
October 2, 2024
·
3 min read
·
Angela Gabriel
Drug Development
Bayer’s Finerenone Hits Primary Endpoint in Phase III Heart Failure Trial
With the late-stage win, Bayer announced Monday that it plans to talk to regulators about seeking approval in an indication that is central to its $3 billion-plus peak sales forecast.
August 5, 2024
·
2 min read
·
Nick Paul Taylor
Earnings
Bayer Touts ‘Modest’ Q2 Performance Amid Sweeping Reorganization
Bayer’s surprising growth in the second quarter was driven in large part by two pharma products: the prostate cancer drug Nubeqa and the chronic kidney disease treatment Kerendia.
August 6, 2024
·
2 min read
·
Tristan Manalac
1 of 21,535
Next
